Search NLS News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any […]

How to build a strong team with the right expertise and mindset for an aggressive growth journey, while trying to survive the next month, is a challenge that many companies, not least startups is now facing. In the running up to the third stop of Haeger & Carlsson’s Ticket to Ride Nordics Tour (a seminar […]

Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The move to Research Triangle Park follows Immunovia’s model development study and completion of the discovery phase for its next-generation test in November 2023. Following these developments, the company will focus […]

About half of the 26 employees were made redundant prior to the bankruptcy and the other half have had their employment agreements terminated following the bankruptcy. As things stand, most of the members of the leadership team are available for a short period of time to ensure compliance with applicable regulatory requirements and to assist […]

The company has announced the successful closure of an oversubscribed bridge financing round. Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis […]

Recently, the annual Entrepreneur’s Gala took place at Uppsala Castle to honor companies that showed exceptional performance during the past year and the Entrepreneur of the Year award was awarded to Ulrika Hammarström, CEO and Founder of Scandinavian CRO (SCRO). This prize is awarded by jury to an entrepreneur who has performed above and beyond […]

If Taylor Swift opined on the status of CNS disease treatments, she might say this is the “promising” era. It is hard to determine if the field of central nervous system (CNS) disease treatment is entering a “new era” of definitive breakthroughs or incremental advancements. At times it seems like a Cambrian explosion of innovation, […]

Researchers at Chalmers University of Technology in Sweden have carried out one of the largest studies to date using AI (artificial intelligence)-assisted image analysis of lymphoma. “An AI-based computer system for interpreting medical images also contributes to increased equality in healthcare by giving patients access to the same expertise and being able to have their […]

The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed, states the company. “Triple-negative breast cancer is a very aggressive disease with poor prognosis. The […]

Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]